MedTrace Logo

Study of Association of Salivary Adipokines With Prediabetes and Type 2 Diabetes Mellitus

NCT03901248 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2020-01-10

No results posted yet for this study

Summary

India has more than 65 million adults with Type 2 Diabetes Mellitus (T2DM) and also has a large number with subclinical stages of glycaemia including impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). At present people with high risk of diabetes are identified by blood test such as Oral glucose tolerance Test and/or glycosylated haemoglobin A1c (HbA1c). Dysregulated actions of adipokines have major roles in development of metabolic diseases such as diabetes. Adipokines influence systemic insulin resistance and also regulate inflammatory process and/or are likely to have major pathological role in the development of diabetes. It is also likely that these abnormalities occur even in sub clinical stages of T2DM which when identified would provide an early opportunity to institute early intervention using life style changes which are proven to be effective in all ethnic groups.The measurements of adipokines such as adiponectin, apelin, visfatin and vaspin which have inter related regulatory roles, in saliva if found to be sensitive would provide a non-invasive, simple method of assessing persons with high risk of T2DM.

Conditions

  • Type2 Diabetes Mellitus

Interventions

OTHER

No Intervention

Observational study

Sponsors & Collaborators

  • India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals

    lead OTHER

Principal Investigators

  • Dr.Ramachandran Ambady, MD,PhD,DSc · President, India Diabetes Research Foundation

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2019-09-30
Completion
2019-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03901248 on ClinicalTrials.gov